PTC Therapeutics (BH3) AI Stock Analysis
PTC Therapeutics
(XETRA:BH3)
No summary available
PTC Therapeutics (BH3) vs. iShares MSCI Germany ETF (EWG)
- Market Cap
- EUR 5.09B
- Dividend Yield
- ―
- Average Volume (3M)
- 103
- Price to Earnings (P/E)
- -52.0
- Beta (1Y)
- 0.44
- Revenue Growth
- -39.87%
- EPS Growth
- -112.41%
- Country
- Germany
- Employees
- 991
- Sector
- Healthcare
- Sector Strength
- 51
- Industry
- Biotechnology
PTC Therapeutics Business Overview & Revenue Model
Company Description
PTC Therapeutics, Inc. (PTCT) is a biopharmaceutical company committed to the research, development, and commercialization of innovative therapies for patients afflicted with rare genetic disorders. Its robust pipeline encompasses both commercialized...
PTC Therapeutics Earnings Call Summary
The call was strongly positive, driven by record product revenue, a more than 100% year-over-year increase in product revenue, raised 2026 guidance, strong Sephience launch momentum, a large remaining PKU opportunity, progress across the pipeline and a strengthened cash position. The main challenges were generic pressure on Emflaza, the lack of expected repeat government orders for Translarna in the fourth quarter, pending international reimbursement decisions, cumulative Sephience discontinuations in the low 20% range and the delayed votoplam FDA meeting. Highlights significantly outweighed lowlights.
Q3-2026 Updates
Positive Updates
Negative Updates
Company Guidance
PTC Therapeutics raised full year 2026 product revenue guidance to $960 million to $990 million and now expects total revenue of $1.29 billion to $1.32 billion, representing 64% to 69% year-over-year product revenue growth, and expects to achieve cash flow breakeven in 2026; international revenue is expected to continue to grow with acceleration points as access and reimbursement are achieved in additional countries over the course of 2027, ST-920’s rolling BLA submission is expected to be completed in Q4 2026 with the potential for approval and commercial launch in 2027, the votoplam Type C meeting is now planned for the first quarter of 2027 and INVEST-HD is planned to enroll approximately 770 early symptomatic patients, PROVE-FA is expected to enroll approximately 120 individuals between 7 and 21 years of age, pricing and reimbursement in France, Italy and Spain are anticipated to be finalized somewhere in the first half of 2027, PTC303 is on schedule to enter the clinic in 2027, and the company believes ST-920 could be accretive in 2027 and remains confident in the $2 billion-plus peak sales opportunity for Sephience.
PTC Therapeutics Risk Analysis
PTC Therapeutics disclosed 53 risk factors in its most recent earnings report. PTC Therapeutics reported the most risks in the "Tech & Innovation" category.
Latest Risks Added
0 New RisksPTC Therapeutics Peers Comparison
Overall Rating
SRPT58Neutral
STOK52Neutral
IONS48Neutral
DYN47Neutral
RARE47Neutral
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| SRPT | 58Neutral | $1.94B | -12.88 | -9.96% | ― | -20.44% | -349.84% |
| STOK | 52Neutral | $1.72B | -7.12 | -67.30% | ― | -86.28% | -634.38% |
| Sector * | 51Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
| IONS | 48Neutral | $6.85B | -11.68 | -110.84% | ― | -7.49% | -98.12% |
| DYN | 47Neutral | $3.23B | -5.42 | -64.30% | ― | ― | 13.71% |
| RARE | 47Neutral | $1.61B | -2.85 | 392.35% | ― | 17.50% | -5.66% |
* Healthcare Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| DE:BH3 | PTC Therapeutics | 60.30 | -0.70 | -1.15% | |
| IONS | Ionis Pharmaceuticals Inc. | 40.42 | -34.26 | -45.88% | |
| SRPT | Sarepta Therapeutics Inc. | 18.54 | -0.13 | -0.70% | |
| RARE | Ultragenyx Pharmaceutical, Inc. | 16.63 | -15.24 | -47.82% | |
| STOK | Stoke Therapeutics | 26.99 | 4.17 | 18.27% | |
| DYN | Dyne Therapeutics, Inc. | 18.05 | -2.85 | -13.64% |
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.